ARYCX | VGSIX | ARYCX / VGSIX | |
Total Expense Ratio | 2.15 | 0.27 | 796% |
Annual Report Gross Expense Ratio | 2.15 | 0.27 | 796% |
Fund Existence | 18 years | 29 years | - |
Gain YTD | 2.112 | 4.920 | 43% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 2500 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 560M | 63.8B | 1% |
Annual Yield % from dividends | 1.06 | 3.75 | 28% |
Returns for 1 year | 7.04 | 8.10 | 87% |
Returns for 3 years | -2.59 | 9.41 | -28% |
Returns for 5 years | 12.07 | 41.03 | 29% |
Returns for 10 years | -0.58 | 63.27 | -1% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
APCB | 29.40 | 0.02 | +0.07% |
ActivePassive Core Bond ETF | |||
XTR | 29.03 | N/A | N/A |
Global X S&P 500® Tail Risk ETF | |||
BIB | 52.55 | -0.07 | -0.14% |
ProShares Ultra Nasdaq Biotechnology | |||
FICS | 39.48 | -0.15 | -0.38% |
First Trust Intl Developed Cap Strth ETF | |||
IJR | 112.91 | -1.24 | -1.09% |
iShares Core S&P Small-Cap ETF |